1-Methyl-3-hydroxymethyl-4,5,6,7-tetrahydro-1H-indazole | 82071-65-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-Methyl-3-hydroxymethyl-4,5,6,7-tetrahydro-1H-indazole
• 英文别名: (1-Methyl-4,5,6,7-tetrahydroindazol-3-yl)methanol
• CAS: 82071-65-6
• 化学式: C₉H₁₄N₂O
• 分子量: 166.223
• InChiKey: SZIYCKIXXXYJGJ-UHFFFAOYSA-N

物化性质

• 熔点：
  97-98 °C
• 沸点：
  328.2±37.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (1-Methyl-4,5,6,7-tetrahydroindazol-3-yl)methyl acetate 、 sodium hydroxide 以12%的产率得到
  参考文献：
  名称：

  DOLMAZON, R.;GELIN, S., J. HETEROCYCL. CHEM., 1982, 19, N 1, 117-121

  摘要：

  DOI：

文献信息

• [EN] CERTAIN SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE<br/>[FR] CERTAINES PYRIMIDINES SUBSTITUÉES, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BIOGEN IDEC INC

  公开号：WO2010117425A1

  公开（公告）日：2010-10-14

  Provided are certain Hsp90 inhibitors, i.e., compounds of Formula I and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use and preparation.

  提供了某些Hsp90抑制剂，即Formula I的化合物及其药用盐、药物组合物以及它们的使用和制备方法。
• Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
  申请人：CS PHARMATECH LIMITED

  公开号：US10435388B2

  公开（公告）日：2019-10-08

  The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R2, R3, R10, E1, E2, E3, Y, and Z are as defined herein.

  本发明提供了式(I)化合物或其亚属结构或种类或其药学上可接受的盐、酯、溶液剂和/或原药，以及用于治疗或改善异常细胞增殖性疾病（如癌症）的方法和组合物，其中A、R2、R3、R10、E1、E2、E3、Y和Z如本文所定义。
• Dolmazon, Rene; Gelin, Suzanne, Journal of Heterocyclic Chemistry, 1982, vol. 19, p. 117 - 121
  作者：Dolmazon, Rene、Gelin, Suzanne

  DOI：——

  日期：——
• PHENOXYMETHYL DERIVATIVES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20180201588A1

  公开（公告）日：2018-07-19

  The invention provides novel compounds having the general formula (I) wherein R A , R B , R C , R C1 and W are as defined herein, compositions including the compounds and methods of using the compounds.
• SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE
  申请人：CS PHARMATECH LIMITED

  公开号：US20190023689A1

  公开（公告）日：2019-01-24

  The present invention provides compounds of Formula (I) or a subgeneric structure or species thereof or a pharmaceutically acceptable salt, ester, solvate, and/or prodrug thereof and methods and compositions for treating or ameliorating abnormal cell proliferative disorders, such as cancer, wherein A, R 2 , R 3 , R 10 , E 1 , E 2 , E 3 , Y, and Z are as defined herein.